Ciclesonide
Chemical compound
![]() |
|
![]() |
|
Clinical data | |
---|---|
Other names | (11β, 16α)-16, 17-[[( R )-cyclohexylmethylene] bis (oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione |
AHFS / Drugs.com | Monograph |
MedlinePlus | a607008 |
Pregnancy
category |
|
Routes of
administration |
Nasal inhalation |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard ( EPA ) | |
ECHA InfoCard |
100.210.908
![]() |
Chemical and physical data | |
Formula | C 32 H 44 O 7 |
Molar mass | 540.697 g·mol −1 |
3D model ( JSmol ) | |
|
|
|
|
![]() ![]() |
Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis . It is marketed under the brand names Alvesco for asthma and Omnaris , Omniair , Zetonna , and Alvesco [1] for hay fever in the US and Canada.
Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings. [2]
It was patented in 1990 and approved for medical use in 2005. [3] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006. [4] It is on the World Health Organization's List of Essential Medicines . [5]
See also
References
- ↑ "Covis Pharma – Products" .
- ↑ Mutch E, Nave R, McCracken N, Zech K, Williams FM (May 2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology . 73 (10): 1657–1664. doi : 10.1016/j.bcp.2007.01.031 . PMID 17331475 .
- ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery . John Wiley & Sons. p. 488. ISBN 9783527607495 .
- ↑ "FDA News Release. FDA Approves New Treatment for Allergies" . Food and Drug Administration . 2006-10-23 . Retrieved 2009-07-30 .
- ↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021) . Geneva: World Health Organization. hdl : 10665/345533 . WHO/MHP/HPS/EML/2021.02.
Further reading
- Rossi S, ed. (2006). Australian Medicines Handbook . Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3 .
Glucocorticoids |
|
||||
---|---|---|---|---|---|
Antiglucocorticoids |
|
||||
Synthesis modifiers | |||||
|
Decongestants
and other nasal preparations (
R01
)
|
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Topical |
|
||||||||||
Systemic use:
Sympathomimetics |
|||||||||||
|
GR |
|
||||||||
---|---|---|---|---|---|---|---|---|---|